
Oncology NEWS International
- Oncology NEWS International Vol 16 No 11
- Volume 16
- Issue 11
GSK and Synta announce STA-4783 collaboration
GSK and Synta announce STA-4783 collaboration
LONDON, UKGlaxoSmithKline and Synta Pharmaceuticals Corp have reached an agreement for the joint development and commercialization of STA-4783 (elesclomol), a first-in-class, small-molecule oxidative stress inducer that is entering phase III development for the treatment of metastatic melanoma (see page 19). The companies will share responsibility for development of STA-4783 in the United States, and GSK will have exclusive responsibility for development outside the US.
Articles in this issue
over 18 years ago
MT103, BiTE antibody, enters phase II testing for ALLover 18 years ago
Sides dig in as ESA policy debate heats upover 18 years ago
Ixempra gets ok for resistant breast cancerover 18 years ago
ASCO adds Oncotype DX to marker guidelineover 18 years ago
Dr. Norton hopes to weed 'molecular' tumor gardenover 18 years ago
Accelerated approval for Tasignaover 18 years ago
Oxidative stress inducer ups survival in advanced melanomaover 18 years ago
FDA removes partial hold on Telcyta clinical developmentover 18 years ago
Should all HER2+ pts receive adjuvant trastuzumab?over 18 years ago
R-CHOP is standard of care for advanced DLBCL patientsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



































